Clinical Genomics Lund

Infrastructure Unit

Contact

ctgservice@med.lu.se

Thoas Fioretos, Platform Scientific Director

thoas Fioretos@med.lu.se

Markus Heidenblad, Head of Unit

markus.Heidenblad@med.lu.se

Ingrid Wilson, Coordinator

ingrid.wilson@med.lu.se

Recent user publications

The publications in this database are the result of research conducted at the units of SciLifeLab – both in user projects and technology development.

A Gradual Transition Toward Anaplasia in Wilms Tumor Through Tolerance to Genetic Damage.

K. Uno, B. Rastegar, C. Jansson, (…), D. Perotti, LH. Mengelbier, D. Gisselsson,

Mod. Pathol.37 (1) 100382

Single-cell transcriptomics of human traumatic brain injury reveals activation of endogenous retroviruses in oligodendroglia.

R. Garza, Y. Sharma, DAM. Atacho, (…), A. Kirkeby, J. Jakobsson, N. Marklund,

LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification.

R. Garza, DAM. Atacho, A. Adami, (…), Z. Kokaia, CH. Douse, J. Jakobsson,

Sci Adv9 (44) eadh9543

UROSCAN and UROSCANSEQ: a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice – from biobank to RNA-sequencing in real time

F. Liedberg, J. Abrahamsson, C. Bernardo, (…), C. Larsson, G. Sjödahl, P. Eriksson,

Scandinavian Journal of Urology57 (1-6) 2-9

SciLifeLab / Services / Our infrastructure / Clinical Genomics Lund

Clinical Genomics Lund

Clinical Genomics Lund was established in 2016 as a joint strategic initiative between the Medical Faculty at Lund University and the Division of Laboratory Medicine, Medical Services, Region Skåne. The unit encompasses two centers, Center for Translational Genomics (CTG) and Center for Molecular Diagnostics (CMD) that are fully aligned and operate in tight synergy, but with separate responsible bodies and budgets (Lund University and Region Skåne, respectively). Clinical Genomics Lund aims to provide state-of-the-art next generation sequencing (NGS)-based services to strong and high-profile translational research projects and to implement new NGS-based tests for clinical diagnostics within the healthcare system aiming at broader national coverage and consensus.

Applications

We provide expertise, method development and end-to-end service to translational research and precision diagnostics for the development of tomorrow’s diagnostics. Our current disease focus areas are:

Cancers (including solid tumors and hematological malignancies)
Rare inherited disease
Microbial diseases and surveillance

Services

Our national services within NGS and other molecular technologies include development of methods for clinical implementation or translational research with strong clinical utility. These include, but are not restricted to:

Consultation (Project design)
QC of samples for various analyses (Sequencing data, Genomic DNA/RNA)
Sequencing:
- DNA sequencing (WGS, WES, Panels, microbial genomes)
- RNA sequencing (total RNA, mRNA, single cell)
User access service (DNA/RNA concentration measurements, Sequencing)
Bioinformatics (Software support , Bioinformatic analysis (data generated at CG or elsewhere))

Equipment

Various automatic robotic systems (BRAVO NGS Workstation)
Various systems for QC, quantification and fragment analyses (TapeStation, Quantification using fluorescent assay (Qubit, Quantit), Agilent Femto Pulse)
Sequencing platforms
- Illumina (NextSeq 2000, NovaSeq 6000, NovaSeq X)
- Nanopore (MinION)
- 10x Genomics (Chromium X, CytAssist)
- Other single-cell equipment (iCell8 cx, Cellaca)

Accessing the Local Unit

For more information about our services, please visit our websites:

Center for Translational Genomics (CTG)

Center for Molecular Diagnostics (CMD)

Clinical Genomics platform

If you do not find the service or technology you require, contact us at info-clinical-genomics@scilifelab.se

Visit the CG platform Website